Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2014

View Archived Issues

A non-cancerous FGF-19 variant for the treatment of liver disease

Panther secures option agreement on numonafide with Northwestern University

Targazyme receives SBIR award to study TZ-101-treated stem cell therapy in oral mucositis

Avanir initiates phase II study of AVP-786 in major depressive disorder; updates on AVP-923

Scientists in the U.S. patent novel inhibitors of Rho GTPase activation

New NS5B inhibitors prepared by Merck & Co.

Sientists at Cortendo patent new cytochrome P450 inhibitors

Identification of a transporter protein central to the erythrocytic cycle in Plasmodium parasites

Actinogen to acquire Corticrine

Saniona extends collaboration with Janssen Pharmaceutica

Velphoro receives marketing authorization in Europe

Merck & Co. divulges new mGlu4R PAMs

Takeda Pharmaceutical describes new M4 receptor agonists

Novel class of pan-pim inhibitors as potential oncolytics presented by Amgen

Live cell encapsulation technology plus low dose anticancer drugs, a novel approach

Bellcium Pharmaceuticals completes Series C financing

RedHill Biopharma amends protocol for phase III H. pylori study of RHB-105

FDA grants priority review to ivabradine for chronic heart failure

MEDI-6383 to be evaluated in phase I trial in patients with solid tumors

FDA grants orphan drug status to Iressa and Zelboraf for cancer

DC Bead approved in China for tumor embolization

Second DSMB review recommends continuation of GRASPA-ML study

Biothera receives NIH grant to continue development of antifungal vaccine

European Commission approves Bristol-Myers Squibb's Daklinza for HCV

Repros Therapeutics' Androxal superior to AndroGel in pivotal phase III trial in hypogonadism

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...